Dose reduction should be done for which of the following anticancer drug, if Allopurinol is used
**Core Concept**
The interaction between allopurinol and certain anticancer drugs is a concern in oncology, particularly when managing patients with gout or high uric acid levels. Allopurinol is a xanthine oxidase inhibitor that can increase the levels of mercaptopurine and azathioprine, leading to toxicity.
**Why the Correct Answer is Right**
When allopurinol is used in conjunction with mercaptopurine or azathioprine, it inhibits the metabolism of these drugs by xanthine oxidase. This results in increased levels of the active metabolites of mercaptopurine (6-thioguanine nucleotides) and azathioprine (6-mercaptopurine ribonucleotides), which can lead to severe bone marrow suppression, liver toxicity, and gastrointestinal side effects. To mitigate this risk, the dose of mercaptopurine or azathioprine should be reduced when allopurinol is co-administered.
**Why Each Wrong Option is Incorrect**
* **Option A:** Not applicable, as the interaction is specific to xanthine oxidase inhibitors and certain anticancer drugs.
* **Option B:** Not relevant, as the interaction is not related to the mechanism of action of this drug.
* **Option C:** This option is not correct, as the interaction is specific to xanthine oxidase inhibitors and certain anticancer drugs, not all chemotherapy agents.
**Clinical Pearl / High-Yield Fact**
When managing patients on allopurinol and concomitant chemotherapy, it is essential to monitor for signs of toxicity, such as bone marrow suppression, liver enzyme elevations, and gastrointestinal symptoms. Dose adjustments of the anticancer drugs may be necessary to prevent adverse effects.
**Correct Answer:** C. Azathioprine.